News

SARA Pharm Solutions will exhibit at Pharma ChemOutsourcing event on September 18-20, 2017 in Long Branch, NJ, USA.
Please feel free to stop by our stand or contact us in order to arrange a meeting.

We are proud that the Nifuroxazide polymorph screening case-study performed in-house by SARA Pharm was recently published in CrystEngComm: http://pubs.rsc.org/en/content/articlelanding/2017/ce/c7ce00303j#!divAbstract.

SARA Pharm Solutions will attend Biotech Outsourcing Strategies cmc on 27th & 28th June 2017, in Basel, Switzerland.

Please contact us in order to arrange a meeting.

SARA Pharm Solutions will participate in CPhI Worldwide in Barcelona, Spain, 4th-6th October, 2016.

Please contact us in order to arrange a meeting.

Sara Pharm scientists, together with University “Politehnica” of Bucharest, Faculty of Applied Chemistry and Material Science, “Ilie Murgulescu” Institute of Physical Chemistry, National Institute of Research and Development for Biological Sciences, Centre of Bioanalysis, National Institute of Materials Physics and the Center for Organic Chemistry C.D. Nenitescu managed to develop an efficient synthesis method for obtaining pure phase W2C at low temperatures (<1050 C),

through the carbothermal reduction of tungsten oxide species in the presence of metallic palladium nanoparticles obtained in situ. The resulting composite materials contain Pd(0) and W2C particles well-dispersed on carbon, with sizes between 50 and 500 nm, showing promise as as potential anode materials for the electro-oxidation of formic acid. The full paper can be accessed here: http://dx.doi.org/10.1016/j.jallcom.2016.05.022

This work was supported by the Romanian grant POSCCE O2.3.3.

  1. 1557/2011 (SARELCAT) carried out at Sara Pharm.

Sara Pharm Solutions scientists, together with University „Politehnica” of Bucharest, Faculty of Applied Chemistry and Materials Science, Chemical Engineering Department, managed to study m-xylene catalytic combustion in a laboratory set-up, over a commercial Pt/Alumina catalyst, using concentrations typical for depollution applications. The operating conditions consisted in temperatures within the interval 120-360 oC, hydrocarbon concentration in the range of 450-1300 ppmv and WHSW (volume flow rate to catalyst weight ratio) between 0.067 and 0.2 m3kg-1s-1. In these conditions was observed a negative reaction order in respect with the m-xylene, a total m-xylene combustion being obtained at temperatures above 250 oC. A power law kinetic model was found to adequately correlate the experimental data. More information is available at http://www.scientificbulletin.upb.ro/rev_docs_arhiva/full8ca_174859.pdf

Sara Pharm Solutions will attend Horizon 2020 Health Partnering Day 2016 in Brussels on July 7th, 2016.

Please contact us in order to arrange a meeting.

Sara Pharm Solutions scientists, together with University „Politehnica” of Bucharest, Faculty of Applied Chemistry and Materials Science, Chemical Engineering Department, managed to study the combustion kinetics of the cyclooctane and o-xylene, alone and in their binary mixture, have been experimentally investigated over a commercial Pt/γ-alumina catalyst. The studies were carried out in a laboratory set-up, with diluted hydrocarbon-air mixtures, typical for depollution applications. The experiments were conducted at atmospheric pressure and temperatures between 140 and 400 °C, hydrocarbons concentration 200–1000 ppmv and WHSW (mass flow rate to catalyst weight ratios) in the range 280–590 h−1. The results evidenced an important inhibition of cyclooctane combustion by the presence of o-xylene, throughout the working domain. Based on the experimental measurements and postulating surface mechanisms, rate expressions were developed for the combustion of the two hydrocarbons, in pure state and as binary mixtures. The cyclooctane was found to react by an Eley–Rideal type mechanism, whereas the o-xylene combustion was explained by a Langmuir-Hinshelwood scheme. More information is available at http://www.sciencedirect.com/science/article/pii/S0263876215002579

SARA Pharm Solutions was approved by the National Agency for Medicine and Medical Devices for physico-chemical testing, stability testing,
method validation and development on API and final products, obtaining Good Manufacturing Practice (GMP) certification.

Approved testing activities:

1. Physicochemical testing:
XRPD – X-Ray Powder Diffraction;
DSC – Differential Scanning Calorimetry;
TGA – Thermogravimetric analysis;
HPLC – High- Performance Liquid Chromatography;
– melting point;
– freezing point;
– solubility;
– aspect and coloration of solutions;
– loss on drying;
– pH determination;
– water determination;
– potentiometric titration.

2. Stability testing: accelerated and long term conditions.

3. Development and validation of analytical methods.

You can view the authorization here.

Sara Pharm Solution has carried out an in-house research program towards the development of shape-stabilized phase change materials. Together with scientists from University “Politehnica” of Bucharest and the “Ilie Murgulescu” Institute of Physical Chemistry, our team developed new shape-stabilized materials with large heat of fusion values (up to 124 kJ/kg) and a theoretical model to help others design better such materials. You can read more in the Journal of Physical Chemistry C paper, at http://dx.doi.org/10.1021/acs.jpcc.5b02608